A new independent report by economics consultancy Oxera has underlined the critical importance of the UK generic medicines sector and how, via free competition, it provides sustained and significant savings to the NHS creating greater patient access.
The in-depth study, commissioned by the BGMA, found that average actual manufacturer selling prices for readily available generics are typically around half the Drug Tariff or reimbursement price - the cost that the NHS pays for a medicine.
The Oxera analysis concluded that the market for the supply of generic medicines in the UK is functioning well and delivering significant price reductions following loss of patent exclusivity from originators.
For further information contact Jeremy Durrant on 02078667883 / 07792918648 or email email@example.com
To download a copy of the report, please read the disclaimer and fill in your details.